Amazing Fenbendazole
by Green Mountain Greenery
Updated: 03/24/2025
Disclaimer:
This information is strictly for research and educational purposes. It is not intended as medical, doctor or veterinary advice. Consultation with a qualified doctor or veterinarian is always recommended before administering any medication or supplement,
What is Fenbendazole and How It's Made:
Fenbendazole is a benzimidazole anthelmintic often used to treat parasitic infections in animals. It is synthesized chemically in laboratories through a multi-step process involving the combination of different chemical compounds to form the final molecular structure that effectively targets parasites. In simple terms, it starts with basic chemical building blocks that are assembled and modified to produce a compound that is potent against certain parasites. The manufacturing of fenbendazole ensures careful control of its chemical reactions and purity standards to produce a safe and effective pharmaceutical product.
Mechanism of Action:
Fenbendazole is a broad-spectrum benzimidazole anthelmintic commonly used in dogs to treat a variety of gastrointestinal parasites. It works by binding to parasite β-tubulin, disrupting microtubule function and leading to parasite death
(Garcia et al., 2020; Merck Veterinary Manual).
Pharmacokinetics:
Fenbendazole has relatively poor gastrointestinal absorption, though it can be slightly enhanced by administering it with food (preferably containing some fat). After absorption, fenbendazole is incompletely metabolized into active sulfoxide and sulfone metabolites
(Bowman & Fogelson, 2018).
Safety Profile:
Fenbendazole is generally considered safe for adult dogs at recommended doses, with minimal reported adverse effects such as mild gastrointestinal upset
(DiPietro & Todd, 1995).
How Fenbendazole Removes Parasites:
Fenbendazole is an anthelmintic, which means it is a type of medication used to treat infections caused by worms. It works by interfering with the glucose uptake of parasitic worms. Parasites rely on glucose as their primary source of energy. Fenbendazole inhibits the parasite's ability to absorb glucose, effectively starving the parasite and leading to its death. This process involves binding to tubulin protein, inhibiting its polymerization into microtubules which are necessary for internal transport and structure within the parasite, thereby disrupting essential cellular processes.
Dosing Disclaimer:
While we cannot officially recommend dosing for internal use, we are committed to providing resources that may aid in your decision-making. It is essential to critically evaluate their accuracy based on your individual understanding and consultation with healthcare professionals.
Its also important to remember never to underdose, if anything being slightly over the mark will ensure parasite removal and minimal to zero complications.
One valuable resource:
Ensure to Translate the site to English:
Reference for animals:
For a good reference for animals you can take a look at already established options. For example lets take a look at safe-guard canine dewormer. They approve their product for dogs 6 weeks and older. Their product contains 222mg of fenbendazole per 1 gram of powder. They explain a daily dose of Safe-guard (which contains 222mg of fenbendazole) is 50mg/kg or 22.68 mg/lb. of weight.
They suggest that a 10lb dog receive 1 gram or 222mg of fenbendazole formulation for 3 days in a row. They caution not to give fenbendazole to a dog that is currently sick. They say dogs over 6 months of age should be dewormed twice a year.
Research Note: We gave our terminally ill 12 year old pitbull a 30 day dose (1.7 grams per day, she's 65lb) and she pulled through her illness. She had swollen glands in neck and in arm pits and was coughing (most likely from worms). After the 30 days the symptoms went away but slowly came back until we did another round a few weeks later.
Safe-guard claims fenbendazole kills only one type of tape worm, the taenia species. They explain that round worm and hookworms can cause significant dangers. They claim fenbendazole kills Roundworm species: Toxocara canis and Toxascaris Leonina. Also that it kills Hookworm species: Ancylostoma caninum, and uncinaria stenocephala and whipworm species: Trichuris vulpis.
They suggest that a 10lb dog receive 1 gram or 222mg of fenbendazole formulation for 3 days in a row. They caution not to give fenbendazole to a dog that is currently sick. They say dogs over 6 months of age should be dewormed twice a year.
Research Note: We gave our terminally ill 12 year old pitbull a 30 day dose (1.7 grams per day of 99% pure Fenbendazole, she's 65lb) and she pulled through her illness. She had swollen glands in neck and in arm pits and was coughing (most likely from worms). After the 30 days the symptoms went away but slowly came back until we did another round a few weeks later.
Safe-guard claims fenbendazole kills only one type of tape worm, the taenia species. They explain that round worm and hookworms can cause significant dangers. They claim fenbendazole kills Roundworm species: Toxocara canis and Toxascaris Leonina. Also that it kills Hookworm species: Ancylostoma caninum, and uncinaria stenocephala and whipworm species: Trichuris vulpis.
Safeguard Doses Converted for 99%:
Safe-guard canine dewormer suggests a daily dose of Safe-guard (which contains 222mg (22%) of fenbendazole) is 50mg/kg or 22.68 mg/lb. of weight. Below is a reference of these doses converted for a 99% fenbendazole product.
• 10 lb → old bracket dose: 1 g → new dose: 0.23 g
• 15 lb → old bracket dose: 2 g → new dose: 0.46 g
• 20 lb → old bracket dose: 2 g → new dose: 0.46 g
• 25 lb → old bracket dose: 3 g → new dose: 0.69 g
• 30 lb → old bracket dose: 3 g → new dose: 0.69 g
• 35 lb → old bracket dose: 4 g → new dose: 0.93 g
• 40 lb → old bracket dose: 4 g → new dose: 0.93 g
• 45 lb → old bracket dose: 5 g → new dose: 1.16 g
• 50 lb → old bracket dose: 5 g → new dose: 1.16 g
• 55 lb → old bracket dose: 6 g → new dose: 1.39 g
• 60 lb → old bracket dose: 6 g → new dose: 1.39 g
• 65 lb → old bracket dose: 7 g → new dose: 1.62 g
• 70 lb → old bracket dose: 7 g → new dose: 1.62 g
• 75 lb → old bracket dose: 8 g → new dose: 1.85 g
• 80 lb → old bracket dose: 8 g → new dose: 1.85 g
• 85 lb → old bracket dose: 9 g → new dose: 2.08 g
• 90 lb → old bracket dose: 9 g → new dose: 2.08 g
• 95 lb → old bracket dose: 10 g → new dose: 2.31 g
• 100 lb → old bracket dose: 10 g → new dose: 2.31 g
• 105 lb → old bracket dose: 11 g → new dose: 2.54 g
• 110 lb → old bracket dose: 11 g → new dose: 2.54 g
• 115 lb → old bracket dose: 12 g → new dose: 2.78 g
• 120 lb → old bracket dose: 12 g → new dose: 2.78 g
• 125 lb → old bracket dose: 13 g → new dose: 3.01 g
• 130 lb → old bracket dose: 13 g → new dose: 3.01 g
• 135 lb → old bracket dose: 14 g → new dose: 3.24 g
• 140 lb → old bracket dose: 14 g → new dose: 3.24 g
• 145 lb → old bracket dose: 15 g → new dose: 3.47 g
• 150 lb → old bracket dose: 15 g → new dose: 3.47 g
Mixing Fenbendazole:
Fenbendazole is Hydrophobic, which means it does not mix with water and instead floats on the surface. Fenbendazole binds with proteins so mixing with meat or possibly yogurt or coconut oil would be better options. We mix it in with raw meat when feeding to our dogs.
Note: Organic “Ultra+ Cannabidiol” (from GMG) is a great option for a synergistic oil to mix with the FenGuard Powder. Joe Tippens used similar CBD for his protocol and it’s made with a base of all organic mct coconut oil.
Measuring Fenbendazole:
Whenever measuring any powder keep in mind each has a different density, therefore a general rule for weight to volume conversion does not exist. This is why it’s important to use an accurate milligram scale for dosing.
Below are our findings for 99% fenbendazole powder weight vs volume.
1/2 teaspoon (packed) = 1.1 grams
1 teaspoon (packed) = 2.1 grams
Using A Binder with Fenbendazole:
According to veterinary pharmacology references (Plumb’s Veterinary Drug Handbook and other peer-reviewed veterinarian literature), while fenbendazole is generally safe, rapid parasite kill-off can lead to adverse inflammatory responses in some animals, particularly if the parasite burden is large. Most binders should be taken separately (2-3 hours after) from the medication and food to mitigate potential absorption of the medication.
Human medical literature has documented Herxheimer reactions primarily with bacterial die-off (e.g., syphilis, Lyme disease). However, similar mechanisms can apply when large numbers of parasites are killed, releasing antigenic material.
Holistic or integrative practices sometimes suggest “binders” (e.g., activated charcoal, bentonite clay) to help reduce ongoing toxin recirculation in the gut. If no measures are taken to bind or eliminate these toxins (e.g., using recommended supportive therapies, ensuring optimal hydration, using veterinarian-approved supplements), the body may experience heightened inflammatory states, gastrointestinal distress, neurological symptoms, or organ stress.
Potential Toxins or Pathogens Released:
When parasites or other organisms (e.g., endosymbiotic bacteria living within worms) are killed rapidly, the following may be released:
Endotoxins (Lipopolysaccharides, LPS):
Though most commonly associated with Gram-negative bacteria, parasitic infections can harbor bacterial symbionts. When these bacteria die, they can release LPS.
LPS is known to provoke inflammatory responses and can contribute to systemic “die-off” or inflammation.
Parasite Antigens (Excretory-Secretory Products):
Worms produce various proteins, peptides, and other antigens during their life cycles. Upon the parasites’ death, a sudden surge of these components can elicit a strong immune response.
These proteins may cause local inflammation, itching, or other immune-mediated effects.
Metabolic Byproducts of Parasite Destruction:
Proteolytic enzymes, cellular debris, or other breakdown products generated when the parasite’s tissues decompose.
Such byproducts can irritate the gastrointestinal lining and potentially impact liver and kidney function if not quickly metabolized and excreted.
Secondary Pathogens:
In some parasitic infections (e.g., filarial worms like Dirofilaria immitis in dogs), symbiotic bacteria (such as Wolbachia) are common. Killing the worms leads to bacterial release, which can further trigger inflammatory responses.
Occasionally, parasites may harbor or disrupt resident microbiota in the host’s gut. The shift in microbiome balance when parasites are killed could stir up additional toxins or alter bacterial populations.
Possible Effects on the Body if No Binders Are Used:
If these toxins or die-off products are not managed (for example, by using binders, ensuring adequate hydration, or other supportive measures), they may accumulate or spread throughout the body more freely. Potential effects include:
Inflammatory Responses:
Systemic inflammation can manifest as fever, chills, muscle aches, or fatigue (similar to a Herxheimer reaction).
Cytokine surges (in response to endotoxins or antigens) can exacerbate joint pain and cause generalized malaise.
Potential Symptom Mitigation with Activated Carbon:
Lowered Endotoxin Levels:
Endotoxins (e.g., lipopolysaccharides from bacteria) can fuel inflammation. Activated carbon may bind some of these molecules in the gut before they enter circulation, theoretically reducing overall inflammatory load (Ref 1, 3).
Decreased Cytokine Surge:
Less endotoxin absorption could reduce local and systemic cytokine release, mitigating symptoms like fever, chills, and joint/muscle pain (Ref 2).
Gastrointestinal Distress:
Increased gastrointestinal upset, diarrhea, or cramping as the gut lining becomes irritated by parasite debris and associated toxins.
Nausea and possible vomiting if the toxin load is high.
Potential Symptom Mitigation with Activated Carbon:
Adsorption of Irritants:
Activated carbon binds potential irritants in the GI tract, which may ease diarrhea, cramping, and nausea (Ref 5, 6).
Less Toxin-Related GI Irritation:
– With reduced exposure to toxic by-products, the gut lining experiences less irritation overall, potentially stabilizing bowel motility (Ref 5).
Neurological Symptoms:
Headaches, brain fog, or dizziness.
These symptoms can be related to inflammatory cytokines and toxin accumulation affecting the central nervous system.
Potential Symptom Mitigation with Activated Carbon:
Indirect Neurological Benefit:
Many neurological symptoms (e.g., headaches, brain fog, dizziness) associated with die-off may be driven by inflammatory mediators and toxins. By binding toxins and reducing systemic circulation, activated carbon use may lessen these symptoms (Ref 3, 7).
Blood-Brain Barrier Considerations:
While activated charcoal acts primarily within the gut, decreased systemic toxin loads can translate to fewer inflammatory signals crossing the blood-brain barrier (Ref 7).
Immune System Over-Stimulation:
Rashes, hives, or other allergic-type responses.
Eosinophilia (an increase in eosinophil count) can happen in parasitic infections themselves and may spike if the immune system is reacting to large amounts of antigenic debris.
Potential Symptom Mitigation with Activated Carbon:
Reduced Allergic-Type Responses:
If fewer toxins and antigens enter the bloodstream, the immune system may be less likely to mount a robust hyper-reactive response (e.g., rashes, hives) (Ref 3, 7).
Overall Immune Balance:
By controlling the source of toxins in the gut, there is potential for a more balanced immune function, lowering the likelihood of cytokine surges and histamine-mediated responses (Ref 1, 7).
Potential Organ Stress:
The liver and kidneys, responsible for detoxification, may become stressed if there is a rapid influx of toxins.
In rare, severe cases, systemic toxicity could lead to hypotension or other more serious complications.
References (Illustrative Examples)
Trewin, H., et al. Activated carbon for the control of toxin release in water systems. Water Research (2016) 91:225–233.
Juang, R. S., et al. Adsorption behavior of several dyes onto activated carbon. Journal of Colloid and Interface Science (2002) 254(2):234–241.
Yang, H., et al. Adsorption of bacterial endotoxin with porous carbon materials. Langmuir (2015) 31(10):3098–3107.
The Merck Veterinary Manual. Activated Charcoal. (Available online)
Contreras, R.G. et al. Activated charcoal as a nonspecific adsorbent in gastrointestinal detoxification: a review. Toxicon (2020) 181:1–9.
McPherson, T., & Pike, R. Activated charcoal usage in outpatient settings. American Journal of Health-System Pharmacy (2018) 75(12):881–889.
Lin, Y. L., & Cheng, T. J. Effects of activated charcoal on inflammatory response. Bioscience Reports (2017) 37(4): BSR20170087.
Good source of zeolite:
What are the Doctors and Studies saying?
Dr. Tom Rogers MD
(Performance Medicine - Knoxville, TN) (https://www.linkedin.com/pulse/fenbendazole-cancer-tom-rogers-md/)
Suggests Several Protocols utilizing Fenbendazole which are interesting:
ACTIVE CANCER TREATMENT
For individuals undergoing active cancer treatment, the following regimen is suggested for potential supportive therapy:
Fenbendazole: Administer one capsule of 444mg daily. Some practitioners recommend taking a break once a week; for instance, you might consider not taking it on Sundays. Though there is no indication that you will develop a tolerance, occasional breaks can be beneficial.
CBD Oil: Enhance the protocol by applying 25mg (1-2 drops) under the tongue each night before bed to potentially induce a calming effect.
Curcumin: To bolster the regimen, consume 600mg twice daily with meals. Curcumin is known for its anti-inflammatory properties which can complement cancer treatments.
Milk Thistle: To support liver function, take 250mg twice daily with meals.
Note: Fenbendazole should be taken with food or after meals to promote optimal absorption.
COMPLEMENTARY CANCER TREATMENT
For comprehensive support alongside conventional cancer therapy:
Fenbendazole: Take one capsule of 222mg daily after a meal that contains fats.
CBD Oil: 25mg (1-2 drops) under the tongue each night before bedtime.
Curcumin: 600mg, twice daily after breakfast and lunch.
Note: Fenbendazole should be taken with food or after meals to promote optimal absorption.
CANCER RELAPSE PREVENTION
To reduce the risk of cancer relapse:
Fenbendazole: Consume one 222mg capsule three times a week, following a fatty meal.
CBD Oil: Apply 25mg under the tongue nightly.
Curcumin: Take 600mg, twice daily with meals.
Milk Thistle: To support liver function, take 250mg twice daily with meals.
Note: Regular monitoring of liver and kidney function by a healthcare professional is recommended and conveniently accessible through standard medical practices.
CANCER PREVENTION (PROPHYLACTIC)
For those at high genetic risk of cancer development:
Fenbendazole: 222mg, three times weekly after a fatty meal, followed by a four-day break. Continue this cycle for 10 weeks, then pause for another 10 weeks.
CBD Oil: Apply 25mg under the tongue nightly.
Curcumin: Take 600mg, twice daily with meals.
Milk Thistle: To support liver function, take 250mg twice daily with meals.
This approach aims at an ongoing regimen for cancer deterrence.
THOUGHTS ON FENBENDAZOLE
Fenbendazole, an antiparasitic with extensive research on its anticancer mechanisms, is a subject of interest due to its promising evidence in vitro (test-tube experiments) and in vivo (live subjects).
Its potential actions include:
Disruption of microtubule polymerization, a major cancer growth inhibition mechanism.
Induction of cell cycle arrest and apoptosis (programmed cell death).
Inhibition of cancerous cell viability and migration.
Sensitization of cells to traditional chemotherapy and radiation.
Although similar in action to Mebendazole, which is FDA-approved and undergoing trials for certain cancers, Fenbendazole is not in clinical trials possibly due to its low cost and widespread availability, limiting economic interest in its research for cancer treatment.
The need for further research and clinical trials, particularly in the context of cancers theoretically induced by mRNA vaccines, remains compelling.
CONCLUSION
Fenbendazole, although not approved by the FDA for cancer treatment in humans, demonstrates a strong safety profile with robust evidence supporting its potential efficacy against several cancer types.
Its companion drug, Mebendazole, is currently being trialed in the U.S. for various cancers, highlighting a call for prompt clinical investigations into Fenbendazole’s applications in oncology.
This exploration is especially pertinent for patients with potential mRNA vaccine-induced cancers, where both Mebendazole and Fenbendazole might offer therapeutic hope.
Source Article:
FENBENDAZOLE and CANCER at least 12 Anti-Cancer mechanisms of action. Not approved by FDA. Cheap. Safe. Kills aggressive cancers. Why no Clinical Trials? Nine research papers reviewed.
“Ivermectin is FDA approved. Fenbendazole is NOT approved for human use by Food and Drug Administration (FDA) and European Medicines Agency (EMA). It is available as a veterinary medication. Fenbendazole is part of a larger group of drugs known as benzimidazoles, which are anthelmintic drugs (i.e., drugs that kill parasitic worms). Another benzimidazole is mebendazole, which can be prescribed to humans with certain parasitic infections. Mebendazole (Vermox) is FDA approved for human use, but it’s signi cantly more expensive.”
- Dr. William Makis MD
He also quoted the Joe Tippens Cancer Protocol:
Fenbendazole: 222mg per day with food (originally 3 days on, 4 days off)
CBD Oil: Apply 25mg under the tongue daily
Curcumin: Take 600mg per day.
Vitamin E: 800IU per day
Fenbendazole Studies:
2023 Jun - Movahedi et al
Repurposing anti-parasite benzimidazole drugs as selective anti-cancer chemotherapeutics
http://anser.press/index.php/ci/article/view/443/486
2023 Apr - Chi-Son Chang et al
Anti-cancer e ect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482585/
2023 Mar - Semkova et al
Redox-mediated Anticancer Activity of Anti-parasitic Drug Fenbendazole in Triple-negative Breast Cancer Cells
https://ar.iiarjournals.org/content/43/3/1207.abstract
2023 Mar - Haebeen Jung et al
Di erential cytotoxic e ects of fenbendazole on mouse lymphoma EL-4 cells and spleen cells
https://www.kjvr.org/journal/view.php?number=3907
2022 Sep - Deokbae Park et al
Anti-cancer e ects of fenbendazole on 5-uorouracil resistant colorectal cancer cells
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437363/
2022 Jan - Li-wen Ren et al
Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724275/
2020 Aug - Deok-Soo Son et al
The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458798/
2020 Jun - Yong Han et al
Involvement of reactive oxygen species in the anti-cancer activity of fenbendazole, a benzimidazole anthelmintic (leukemia)
https://www.kjvr.org/journal/view.php?doi=10.14405/kjvr.2020.60.2.79
2018 Aug - Dogra et al
Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways
